QUIDELORTHO CORP Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
QUIDELORTHO CORP (QDEL) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 0 shares for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.
Financial Statements › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2026-08-07
- QUIDELORTHO CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2026-06-28 was 0.00 shares.
- QUIDELORTHO CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2026-03-29 was 0.00 shares.
- QUIDELORTHO CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-09-28 was 0.00 shares.
- QUIDELORTHO CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-06-29 was 0.00 shares.
- QUIDELORTHO CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2025 was 0.00 shares.
- QUIDELORTHO CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2024 was 0.00 shares.
- QUIDELORTHO CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2023.
- QUIDELORTHO CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2023 was 600.00K shares, a 25.00% decline from fiscal 2022.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month |
|---|---|---|---|---|
| 2026-06-28 | 0.00 shares 10-Q · filed 2026-08-07 | 0.00 shares 10-Q · filed 2026-08-07 | ||
| 2026-03-29 | 0.00 shares 10-Q · filed 2026-05-06 | |||
| 2025-12-28 | 0.00 shares 10-K · filed 2026-02-19 | |||
| 2025-09-28 | 0.00 shares 10-Q · filed 2025-11-06 | 0.00 shares 10-Q · filed 2025-11-06 | ||
| 2025-06-29 | 0.00 shares 10-Q · filed 2026-08-07 | 0.00 shares 10-Q · filed 2026-08-07 | ||
| 2025-03-30 | 0.00 shares 10-Q · filed 2026-05-06 | |||
| 2024-12-29 | 0.00 shares 10-K · filed 2026-02-19 | |||
| 2024-09-29 | 0.00 shares 10-Q · filed 2025-11-06 | 0.00 shares 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 0.00 shares 10-Q · filed 2025-08-06 | 0.00 shares 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 0.00 shares 10-K · filed 2026-02-19 | |||
| 2023-10-01 | 0.00 shares 10-Q · filed 2024-11-08 | 0.00 shares 10-Q · filed 2024-11-08 | ||
| 2023-07-02 | 0.00 shares 10-Q · filed 2024-08-01 | 0.00 shares 10-Q · filed 2024-08-01 | ||
| 2023-04-02 | 500.00K shares 10-Q · filed 2024-05-09 | |||
| 2023-01-01 | 600.00K shares 10-K · filed 2025-02-27 | |||
| 2022-10-02 | 600.00K shares 10-Q · filed 2023-11-02 | 600.00K shares 10-Q · filed 2023-11-02 | ||
| 2022-07-03 | 700.00K shares 10-Q · filed 2023-08-09 | 700.00K shares 10-Q · filed 2023-08-09 | ||
| 2022-04-03 | 500.00K shares 10-Q · filed 2023-05-04 | |||
| 2022-01-02 | 800.00K shares 10-K/A · filed 2024-08-01 | |||
| 2021-10-03 | 800.00K shares 10-Q · filed 2022-11-04 | 800.00K shares 10-Q · filed 2022-11-04 | ||
| 2021-07-04 | 700.00K shares 10-Q · filed 2022-08-05 | 900.00K shares 10-Q · filed 2022-08-05 | ||
| 2021-01-03 | 1.20M shares 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |